AdaptHealth Corp. (AHCO) Q2 2025 Earnings Call Transcript

AdaptHealth Corp. reported Q2 2025 revenue of $800.4 million and adjusted EBITDA of $155.5 million (19.4% margin), while reducing net debt to $1.8 billion and net leverage to 2.81x. The company announced a significant 5-year, $1 billion capitated agreement with a major national healthcare system, projected to generate at least $200 million in new annual revenue once fully ramped by the end of 2026, elevating capitated revenue to over 10% of total. Despite maintaining full-year revenue and free cash flow guidance, adjusted EBITDA guidance was lowered due to infrastructure investments for the new contract and delayed payer rate negotiations. AdaptHealth anticipates reduced cash taxes from the OBBBA tax bill and views its scale as advantageous for navigating potential CMS competitive bidding changes, particularly for CGMs and medical supplies.

Analysis

AdaptHealth Corp. announced a transformational five-year, $1 billion-plus capitated agreement with a major national health system, a strategic win that is projected to add at least $200 million in new annual revenue once fully ramped by the end of 2026. This contract significantly enhances revenue visibility and will increase the mix of recurring capitated revenue to over 10% of the total. The announcement accompanied a solid Q2 2025 performance, with revenue of $800.4 million (flat year-over-year when adjusted for divestitures) and adjusted EBITDA of $155.5 million, yielding a 19.4% margin that was at the high end of the company's guidance. The company also demonstrated strong balance sheet management, reducing its debt balance by $150 million in the quarter and lowering its net leverage ratio to 2.81x, making steady progress toward its 2.5x target. Despite this operational strength, AdaptHealth lowered its full-year 2025 adjusted EBITDA guidance to a range of $642 million to $682 million, citing necessary infrastructure investments to support the new contract and the delay of certain payer rate negotiations into 2026. However, the company maintained its full-year free cash flow guidance of $170 million to $190 million, a move supported by anticipated cash tax reductions from the recently passed OBBBA legislation. Underlying business trends are also improving, with Sleep Health new setups reaching a two-year high and the Diabetes segment showing signs of a turnaround, with a potential return to growth in the second half of the year.

Key Decisions for Investors

• Investors should view the downward revision in 2025 adjusted EBITDA guidance as a strategic investment to support a transformational, $1 billion-plus contract, focusing on the projected $200 million annual revenue ramp-up through 2026 rather than the immediate margin impact.
• Monitor the company’s continued progress on deleveraging towards its 2.5x net leverage target, as its ability to maintain strong free cash flow guidance, bolstered by tax benefits, provides financial flexibility for growth investments and potential M&A without stressing the balance sheet.
• Track the execution of operational turnarounds in the Sleep and Diabetes segments, as sustained momentum could provide an upside to core growth, while also remaining vigilant on developments related to the CMS competitive bidding proposal, which presents both a risk of margin pressure and an opportunity for market share consolidation for a scale operator like AdaptHealth.